Eirini P Papapetrou

List of Publications by Year
in descending order

62	7,732	201674 27	149698 56
papers	citations	h-index	g-index

86	86	86	12764
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood, 2022, 139, 205-216.	1.4	19
2	Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factorâ€“Mutant Neoplasms. Cancer Discovery, 2022, 12, 836-855.	9.4	19
3	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Advances, 2022, 6, 2992-3005.	5.2	7
4	MDS/AML with del5q: An acquired â€œlaminopathyâ€?. Cell Stem Cell, 2022, 29, 498-499.	11.1	0
5	Studying leukemia stem cell properties and vulnerabilities with human iPSCs. Stem Cell Research, 2021, 50, 102117.	0.7	3
6	Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Advances, 2021, 5, 687-699.	5.2	12
7	The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature, 2021, 592, 296-301.	27.8	236
8	Reprogramming and cancer. Stem Cell Research, 2021, 52, 102249.	0.7	2
9	Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell, 2021, 28, 1074-1089.e7.	11.1	37
10	Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology, 2021, 28, 50-56.	2.5	6
11	Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2021, 2185, 411-422.	0.9	1
12	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation, 2021, 144, 1940-1954.	1.6	33
13	Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of SF3B1-Mutant Hematopoietic Stem/Progenitor Cells. Blood, 2021, 138, 147-147.	1.4	0
14	Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein. Scientific Reports, 2021, 11, 24432.	3.3	51
15	Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. Cell Reports, 2020, 31, 107688.	6.4	31
16	Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells. Experimental Hematology, 2020, 87, 25-32.	0.4	5
17	SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia, 2020, 34, 2525-2530.	7.2	61
18	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 2019, 36, 194-209.e9.	16.8	184

#	Article	IF	Citations
19	Modeling Leukemia with Human Induced Pluripotent Stem Cells. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034868.	6.2	7
20	Modeling blood diseases with human induced pluripotent stem cells. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	23
21	Modeling myeloid malignancies with patient-derived iPSCs. Experimental Hematology, 2019, 71, 77-84.	0.4	18
22	Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells. JCI Insight, 2019, 4, .	5.0	10
23	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	4.8	43
24	TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics, 2018, 50, 83-95.	21.4	156
25	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	11.1	114
26	Gene and Cell Therapy for Î²-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. Advances in Experimental Medicine and Biology, 2017, 1013, 219-240.	1.6	5
27	The Activated TGFÎ² Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q. Blood, 2017, 130, 875-875.	1.4	3
28	LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy - Nucleic Acids, 2016, 5, e394.	5.1	1
29	Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine, 2016, 22, 1392-1401.	30.7	131
30	Induced pluripotent stem cells, past and future. Science, 2016, 353, 991-992.	12.6	34
31	Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Molecular Therapy, 2016, 24, 678-684.	8.2	175
32	Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular Therapy - Nucleic Acids, 2016, 5, e284.	5.1	21
33	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. Blood, 2016, 128, 962-962.	1.4	2
34	Modeling myeloid malignancies with human induced pluripotent stem cells. Experimental Hematology, 2015, 43, S39.	0.4	0
35	Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14057.	4.1	49
36	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	17.5	130

#	Article	IF	Citations
37	The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells. Stem Cell Reports, 2015, 4, 658-669.	4.8	7
38	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. Cell Reports, 2014, 8, 1677-1685.	6.4	9
39	CARs Move To the Fast Lane. Molecular Therapy, 2014, 22, 477-478.	8.2	4
40	An iPSC-Based Model Of MDS For Phenotype-Driven Gene and Drug Discovery. Blood, 2013, 122, 859-859.	1.4	0
41	Chromosome 7q Hemizygosity Recapitulates MDS-Related Cellular Phenotypes In Genetically Engineered Human Pluripotent Stem Cells. Blood, 2013, 122, 862-862.	1.4	0
42	FA iPS: correction or reprogramming first?. Blood, 2012, 119, 5341-5342.	1.4	2
43	Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency. Cell Reports, 2012, 1, 99-109.	6.4	61
44	Safe harbours for the integration of new DNA in the human genome. Nature Reviews Cancer, 2012, 12, 51-58.	28.4	391
45	IPS Cells From Del(7q)-MDS Patients Display Impaired Proliferation and Hematopoietic Commitment. Blood, 2012, 120, 174-174.	1.4	0
46	Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nature Protocols, 2011, 6, 1251-1273.	12.0	67
47	Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nature Protocols, 2011, 6, 1274-1289.	12.0	12
48	miR-371-3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. Cell Stem Cell, 2011, 8, 695-706.	11.1	126
49	A bioinformatic assay for pluripotency in human cells. Nature Methods, 2011, 8, 315-317.	19.0	410
50	Genomic safe harbors permit high Î²-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnology, 2011, 29, 73-78.	17.5	277
51	A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Research, 2011, 39, e72-e72.	14.5	64
52	Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian Journal of Pharmacology, 2011, 43, 385.	0.7	8
53	Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression. Blood, 2011, 118, 352-352.	1.4	0
54	A Genetic Strategy for Single and Combinatorial Analysis of miRNA Function in Mammalian Hematopoietic Stem Cells. Stem Cells, 2010, 28, 287-296.	3.2	77

#	Article	IF	Citations
55	Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. Therapeutics and Clinical Risk Management, 2010, 6, 265.	2.0	10
56	Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach. International Journal of Medical Sciences, 2010, 7, 94-100.	2.5	11
57	Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15163-15168.	7.1	389
58	Reconstructing blood from induced pluripotent stem cells. F1000 Medicine Reports, 2010, 2, .	2.9	9
59	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12759-12764.	7.1	262
60	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature, 2009, 461, 402-406.	27.8	808
61	Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology, 2009, 27, 275-280.	17.5	3,047
62	Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. Journal of Clinical Investigation, 2009, 119, 157-68.	8.2	51